Clinical

Panelist discusses how HS Centers of Excellence demonstrate potential for enhanced health care delivery through coordinated, specialized care approaches, with managed care organizations driving adoption through strategic incentives and collaborative frameworks.

Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.

A positive association was found between osteoarthritis and overactive bladder (OAB), but rheumatoid arthritis and psoriatic arthritis were not significantly correlated with the condition.

HIV infections and deaths would increase dramatically should the United States cut back on funding for the President’s Emergency Plan for AIDS Relief (PEPFAR).

In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.

Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.

Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral solution.

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.

An overall increase in life expectancy was observed across all individuals living with HIV but disparities between gender groups persist.

Michael A. Bernstein, MD, Stamford Health, addresses common misconceptions about tuberculosis amid the outbreak in Kansas City, Kansas.

In an interview, Debra Patt, MD, PhD, MBA, FASCO, discusses the priorities of the Community Oncology Alliance as she starts her term as president.

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal intraocular lenses.

In an interview with The American Journal of Managed Care, Michael A. Bernstein, MD, stressed the need for effective communication and proactive screening to curb the recent tuberculosis (TB) outbreak.

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary Cancers Symposium later this week in San Francisco, California.

The number of psychiatrists submitting more than 10 claims to Medicare Part B decreased by 16.8% from 2014 to 2022.

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.

Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.

These new data highlight the need for improved pain management among patients with cancer and survivors.

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

Gladys Antelo-Allen, associate director of Education and Training, Camden Coalition, dives into the essential skills of providing complex care: motivational interviewing, harm reduction, care planning, trauma-informed care, and de-escalation.

A higher Dietary Inflammatory Index score was linked to an increased risk of hypertension in children and adolescents, emphasizing the role of diet in blood pressure regulation.

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.

Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.

Panelist discusses how Centers of Excellence for hidradenitis suppurativa (HS) differentiate through comprehensive, patient-centered multidisciplinary care models integrating specialized dermatologic, surgical, psychological, and pain management interventions to holistically address complex chronic conditions while navigating systemic health care implementation challenges.

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy considerations, with decisions between discontinuation vs switching to alternative BTK inhibitor (BTKi) therapy being influenced by factors such as depth and duration of response, toxicity severity, patient preferences regarding adverse effects and treatment schedules, and quality-of-life considerations.

Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).

Non-Hispanic Black and Hispanic/Latino children were also significantly less likely to receive brain MRI scans compared with their non-Hispanic White peers.